New Jersey-based Leucine uses cutting-edge AI technology to digitise pharmaceutical manufacturing. Now, the company has snapped a $7 million Series A funding round led by Ecolab Inc. that backed Paptic, alongside participation from existing investors, including Pravega Ventures, Axilor Ventures, Techstars, and angels.
Beta launch of AI co-pilot
The company has also announced the beta launch of Leucine10x, a groundbreaking AI framework designed to serve as a co-pilot in pharmaceutical manufacturing processes.
The funding round will support Leucine in refining its AI capabilities and making its AI Co-pilot a trusted partner to the production and quality managers on the shop floor and in expanding its reach to more facilities and customers.
Plans to scale its Compliance Cloud platform
Leucine plans to use the fresh funds to scale its Compliance Cloud platform globally. Compliance Cloud serves as a digital twin of the pharma manufacturing shop floor, bringing real-time performance monitoring, compliance management, and actionable insights to the table.
Leucine sets itself different from some of the legacy digitisation tools with its AI-driven capabilities. These are designed to digitise pharma manufacturing workflows faster and provide proactive insights that enable pharma companies to stay compliant and produce faster and in a cost-effective manner.
Leucine’s platform can be implemented in 8 weeks. This speed of implementation becomes possible because of the proprietary AI-enabled digital process builder based on Large Language Models.
The Leucine10x platform
Leucine10x will revolutionise how decision-making is done in pharma manufacturing, enabling Production and Quality Assurance teams to achieve their organisation goals with ease and confidence. Built on proprietary LLM technology, Leucine10x offers an army of AI co-pilots that perform highly specialised tasks such as digitising paper-based SOPs.
Most significant is their ability to speed up Root Cause Analysis (RCA) of deviations in the manufacturing process by quickly analysing data, including text-based records, logs, and even staff interview transcripts, to identify potential issues or patterns that might not be readily apparent.
Helps produce safer medicines
Founded by Mustaq Singh Bijral and Vivek Gera, Leucine helps make pharmaceutical manufacturing compliant, safer, and faster. Its innovative solutions, from Batch Planning to Batch Release, aim to modernise traditional procedures, replacing paper-based records with a seamless, digital-first approach.
With its AI-driven analytics dashboard, Leucine empowers pharma companies to produce safer and more effective medicines.
Leucine is currently deployed at over 30 companies in over 300 pharma manufacturing facilities across 10 countries, including the US, India, Brazil, Mexico, UAE, and others.
Vivek Gera, founder, and CEO of Leucine, commented: “Paper-based manufacturing records are the industry’s achilles’ heel, fueling not only regulatory nightmares but also ballooning production costs and inefficiencies. The legacy solutions are no better, with their extremely long implementation cycles and rigid, siloed applications that leave manufacturers in a lurch.”
Mustaq Singh Bijral, Co-founder and CPO of Leucine, said: “We’re excited to share that Leucine10x is already operational in select customer facilities under a trusted tester agreement. The response has been incredibly positive, and due to high demand, we’re currently enrolling new customers through a waitlist”.
“Vivek and Mustaq have been relentless in their mission to make pharma manufacturing safer. This latest funding round will enable Leucine to bring the power of LLMs and associated technologies to make significant advances in pharma manufacturing. We couldn’t be happier to support them in this quest,” said Rohit Jain, Co-founder and Partner at Pravega Ventures. Pravega Ventures also invested in the Seed round of Leucine.
